Mahalingam, D., Shroff, R. T., Carneiro, B. A., Ji, Y., Coveler, A. L., Cervantes, A., Sahai, V., Ploquin, A., Hiret, S., LoConte, N. K., Percent, I. J., Lopez, C. D., Pernot, S., Kavan, P., Mulcahy, M. F., Carr, R. M., Giles, F. J., Mazar, A. P., Jaros, M., Bekaii-Saab, T. S. (2026). Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.653